ASML's Structural Re-Rating: BofA Upgrades PT on EUV-Driven Margin Expansion and 2026 Growth Clarity

Bank of America's recent price target hike to $1,886 from $1,868 is a clear vote for a structural shift in ASML's investment case. The firm's conviction is built on a model that sees the company transitioning from a cyclical equipment supplier to a high-quality, margin-expanding growth story. This isn't a minor revision; BofA raised its 2026-2028 earnings per share estimates by approximately 4% to 6%, a significant upward adjustment that signals improved visibility into the company's earnings trajectory.

The core of this bullish thesis is a projected acceleration in revenue growth, driven by two powerful engines. BofA now models 2026 revenue growth of 18.5%, fueled by a 20% year-over-year increase in tool revenues and a 15% year-over-year rise in installed base management sales. This dual-track growth reflects both new capacity demand and the recurring revenue from servicing existing systems. The firm's optimism is grounded in specific execution: it raised its 2026 EUV delivery forecast to 64 units from 61 units, citing pull-ins in DRAM demand, and projects ASML could be running close to full capacity by late 2027.

The most compelling narrative shift is from "wafer fab equipment minus" to "plus." Analyst Didier Scemama argues that the long-standing debate over declining lithography intensity is fading, with the company poised to capture greater market share, particularly in DRAM. This inflection is expected to drive a powerful margin expansion. The firm sees gross margins expanding in 2027. This improvement will be driven by a better product mix and higher utilization, directly translating the revenue growth into superior profitability. For institutional investors, this combination of accelerating top-line growth and a clear path to margin expansion justifies the premium valuation and supports a conviction buy.

Financial Execution and Backlog Validation

The credibility of ASML's ambitious guidance hinges on its ability to convert record backlog into revenue. Recent financial performance provides a strong validation of that execution. In the fourth quarter of fiscal 2025, the company delivered net sales of €9.7 billion and a robust gross margin of 52.2%. More importantly, quarterly net bookings surged to €13.2 billion, with €7.4 billion attributed to EUV systems. This deep order book, coupled with a full-year 2025 sales figure of €32.7 billion and a gross margin of 52.8%, demonstrates the company's current momentum and pricing power.

Bank of America's analysis of the backlog structure further confirms the achievability of the 2025 revenue target. The firm examined the €43.3 billion in customer purchase obligations at the end of 2024 and found that 59% of this total, or €25.5 billion, is expected to be recognized in 2025. This includes a substantial portion from the systems backlog and Installed Base Management. However, the analysis also highlights a specific requirement: to meet its system sales guidance for the year, ASML must book an additional €6.8 billion worth of Deep Ultraviolet (DUV) tools in 2025. This gap underscores the ongoing need for demand across its entire product portfolio, not just the high-margin EUV segment.

Management's 2026 outlook, which calls for total net sales between €34 billion and €39 billion with a gross margin range of 51% to 53%, now faces a higher bar. The institutional view is that this guidance is supported by the existing backlog, with BofA noting that purchase obligations "recognizable beyond '25" amount to €17.8 billion. This provides a solid foundation for the next year's revenue. The key challenge for investors will be monitoring whether the company can consistently fill the DUV booking gap each year while simultaneously scaling EUV production. The recent financials show ASML is executing well, but the path to 2026's ambitious targets requires flawless operational discipline.

Geopolitical and Demand Risks: The China Overhang

The primary structural headwind for ASML is the ongoing geopolitical friction with China, which is expected to exert a persistent drag on near-term revenue. Management has explicitly signaled a significant step-down in the Chinese market's contribution. China's share of total sales fell to 33% in 2025, down from 41% the prior year, and the CFO expects this to decline further to around 20% in 2026. This represents a material shift in the company's demand mix, moving away from a historically large and profitable customer base.

The pressure is most visible in the Deep Ultraviolet (DUV) segment, which remains the only product line subject to export controls but still available for sale to Chinese clients. Sales of these machines decreased by 6% in 2025 to €12 billion, a direct consequence of the market normalization following the post-Covid-19 surge. While management expects demand to "normalise" in 2026, the base case implies a continued softening from the elevated 2025 levels. This creates a specific execution challenge: the company must offset this China-related decline with robust growth elsewhere, primarily from its high-margin EUV systems, to meet its ambitious overall sales targets.

The market's reaction to this narrative is telling. The stock's recent 6.3% drop appears directly tied to renewed investor sensitivity around this 2026 outlook. With the company having rallied strongly into the year on the back of AI-driven EUV demand, any perceived step-down in growth assumptions-particularly from a major regional market-can trigger an outsized pullback. This volatility underscores the high bar set by strong AI demand and the premium valuation that now prices in flawless execution. For institutional investors, this China overhang introduces a clear demand risk that must be weighed against the powerful structural tailwinds from capacity expansion and margin improvement.

Catalysts and What to Watch

For institutional investors, the path forward is defined by a series of near-term milestones that will confirm the structural thesis or expose its vulnerabilities. The first critical test is the upcoming Q1 2026 guidance, which must align with the company's own forecast of total net sales between €8.2 billion and €8.9 billion and a gross margin between 51% and 53%. Given that the full-year 2026 target range is wide, the quarterly print will signal whether execution is on track for the midpoint or if margin pressure is emerging earlier than expected.

The second key metric is the execution of the raised 2026 EUV delivery forecast of 64 units. This target, which includes three additional units expected for SK Hynix, is a direct proxy for capacity utilization and demand strength. Meeting or exceeding this number would validate BofA's optimism around DRAM pull-ins and the company's ability to ramp production. Any shortfall would raise immediate questions about supply chain constraints or softer-than-anticipated demand from key customers.

Finally, investors should watch for any updates on the long-term validation of the 2030 financial targets, particularly the revenue range of €44 billion to €60 billion and the gross margin goal of 56% to 60%. While these are distant, they provide the ultimate benchmark for the margin expansion narrative. Any reaffirmation or refinement of these targets, perhaps at the next Capital Markets Day, will be a major catalyst for the stock, as it would cement the view of ASML as a high-quality, margin-accretive growth story rather than a cyclical equipment supplier. For now, the focus remains on the quarterly and annual execution that must bridge the gap to that ambitious future.